Xun Zhao

Transplant Hepatologist at McGill University Health Center
Trained @McGillGI @UHNTransplant
MSc Candidate Clinical Epidemiology @ihpmeuoft

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Systemic therapy for HCC: Doublets, triplets and beyond
@JHepatology
👉comprehensive summary of systemic therapies in HCC
👇my author link
https://t.co/e9FfJdIIl2
@myESMO @EASLedu @ilca

[Xun Zhao @HepHepHourray]

@laiaaas @UofTGastroHep @UHNTransplant @ArndtVogel Bravo!

[Arndt Vogel @ArndtVogel]

TACE with immunotherapy and anti-angiogenic agents in intermediate- stage HCC (CHANCE2202): a target trial emulation study
@eClinicalMed
https://t.co/Nqo6GnB0oe
👉PFS and OS benefit for combination
🧐RWD are interesting, but not practice changing. Phs-3 studies so far without OS benefit
@myESMO @ASCO @EASLedu @ilca

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
The rise of transplant oncology in primary liver cancer and metastatic disease
@HEP_Journal
https://t.co/vUyWhI1aav
👏fantastic review on Transplant Oncology
👉must read, all you need to know
@myESMO @ASCO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)
@JHepatology
https://t.co/gazLDrF9XA
👉Proof of concept study
👉Implementing immunotherapy before LTx is feasible
@myESMO @ASCO @EASLnews

[Arndt Vogel @ArndtVogel]

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study
@HEP_Journal
👉538 pts 🇮🇹
👉mOS 19.7 mo, 36-month survival rate 30.0%
👉4.4% drug-free disease-free
👉14.1% liver decompensation
@myESMO @ASCO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma
@HEP_Journal
https://t.co/jm0cOxRL0o
👏Timely guideline
👉still very difficult to treat tumor
@ASCO @myESMO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

The role of stereotactic body radiotherapy in the management of HCC with macroscopic vascular invasion: a narrative review
https://t.co/oi2LMyIuCQ
👏excellent review
👉SBRT emerges as a crucial tool in the multidisciplinary management of HCC and has the potential to enhance systemic therapy efficacy
@myESMO @ASCO @EASLnews @ILCAnews

[Arndt Vogel @ArndtVogel]

Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than TACE in HCC
@JHepatology
https://t.co/GDIfBcfAf5
👉5677 LT candidates
👉more complete necrosis, lower likelihood of multiple LRTs & lower risk of waitlist dropout
@myESMO @EASLedu @ASCO @ILCAnews

[Arndt Vogel @ArndtVogel]

Keynote-937 phs-3: pembrolizumab for HCC after surgical resection or local ablation
#ASCOGI26
👉mRFS: 46 vs 45 mo
👉4-yr RFS rate: 50 vs 50%
🧐Very disappointing, but inline with IMBRAVE-050, now we need to invest into neoadj. strategies
@myesmo @ASCO @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

IKF-035/ABC-HCC phase IIIb:Aatezolizumab plus bevacizumab vs TACE in intermediate-stage HCC
#ASCOGI26
👉mTTFS: 14.6 vs 9.5 mo
🧐Interesting interim analysis, but we need more data.
@myesmo @ASCO @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

Nivo/Ipi for potentially resectable HCC: Long-term efficacy & biomarker exploration
@JHepatology
https://t.co/g0ux4oOr7s
👉Nivo Ipi feasible
👉ICI-induced tertiary lymphoid structure associated with antitumor immunity
🧐Adjuvant studies failed, we need now neoadj. phs-III trails
@myESMO @ASCO @EASLedu

[Xun Zhao @HepHepHourray]

@ArndtVogel @TheLancet What do you make of the amount of BCLC B and C patients being considered resectable in this study? Some institutions would have given them IO regardless.

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
LEAP-012 phase 3 study: TACE with lenvatinib + pembrolizumab vs plc for intermediate stage HCC
👉IA just released
👉PFS benefit maintained
👉No OS benefit, study stopped
🧐How to implement in clinical practice? I still consider as an effective option for downstaging/sizing
@myESMO @EASLedu @ilca
👇https://t.co/o7gaWyVIP2

[Arndt Vogel @ArndtVogel]

Camrelizumab + rivoceranib vs direct surgery in resectable HCC at intermediate or high risk
@TheLancet
https://t.co/X8xoMllmDf
🔎CARES-009 phs 2/3
👉Perioperative cam + rivo doubles EFS
🧐Consistent pos. data for the combo, will be interesting to see whether & when approved in the West
@myESMO @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma
#ESMO25 #ESMOAmbassadors
👉 EFS: 42 vs 19 mo
👉 DFS: 42 vs 19 mo
👉 MPR: 35 vs 7%
🧐Very promising results, neoadjuvant strategies will be the future in HCC
@myesmo @EASLedu @ilca

[Xun Zhao @HepHepHourray]

@ArndtVogel @myESMO @EASLedu A very important study!

[Arndt Vogel @ArndtVogel]

IKF-035/ABC-HCC phs IIIb: Atezolizumab + Bevacizumab vs TACE in intermediate-stage HCC
#ESMO25 #ESMOAmbassadors
👉 TTFS: 14 vs vs 9 mo
🧐BCLC B is not any more the ”domain” of local therapies, but intent of treatment is more than ever key for MDT discussion
@myesmo @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

Downstaging of HCC before liver transplantation: Results from a national multicenter prospective cohort study
@HEP_Journal
https://t.co/lkFqjllPh5
👉82% UNOS-DS & 66% AC downstaged
👉Yttrium-90 > TACE for DS
👉post-LT survival comparable, but there may be an upper limit
🧐New ICI based 💊will offer more opportunity
@myESMO @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

🔥hot off the press
👉ESMO-MCBS 2.0 Scorecards now available
🧐Do you agree with the proposed benefit?
👇Check them out for Cholangiocarcinoma
https://t.co/PSWyksRUMB
@myESMO @ILCAnews @EASLedu